Phenomix Sciences launches three-in-one obesity phenotyping test
top of page
Browse by category
Search
Phenomix Sciences has launched a new MyPhenome test that now allows patients to test for all three identified phenotypes - Emotional...
Entera Bio reveals data for oral GLP-2 peptide for short bowel syndrome patients
Entera Bio has revealed positive pharmacokinetic results from its collaborative research combining a proprietary long acting GLP-2...
FDA approves Wegovy for CVD risk reduction in people with overweight or obesity and established cardiovascular disease
The FDA has approved a label expansion for Wegovy based on a supplemental New Drug Application (sNDA) for the indication of reducing...
Epitomee files weight loss capsule for FDA clearance
Epitomee has submitted its weight loss capsule that offers an innovative, orally administered, drug free, and clinically proven as...
Spatz3 Adjustable Gastric Balloon launched in the US
Spatz Medical has announced the launch of the Spatz3 Adjustable Gastric Balloon in the US. The Spatz3 Adjustable Gastric Balloon,...
NICE approves endoscopic sleeve gastroplasty for weight loss management
The UK’s National Institute for Health and Care Excellence (NICE) has approved the use of endoscopic sleeve gastroplasty (ESG) for weight...
First procedures utilising ReShape’s next-generation Lap-Band 2.0 FLEX
ReShape Lifesciences has announced that the first procedures utilising the company’s next generation, enhanced Lap-Band 2.0 FLEX, have...
Innovent's mazdutide accepted by China’s NMPA for chronic weight management
Innovent Biologics’ New Drug Application (NDA) for mazdutide (Innovent R&D code: IBI362), a glucagon-like peptide-1 receptor (GLP-1R) and...
FDA reviewing ProSomnus’ EVO medical device for severe OSA
The FDA has accepted, and is in the process of reviewing, the ProSomnus’ premarket notification for its ProSomnus EVO precision medical...
FDA approves USGI Medical’s pivotal study of the POSE2.0 procedure for primary obesity
The FDA has approved an USGI Medical’s Investigational Device Exemption application to conduct a pivotal study of its POSE2.0...
Browse by tag
bottom of page